Symbols / LIPO $0.02 -61.72% Lipella Pharmaceuticals Inc.
LIPO Chart
About
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 102.58K |
| Enterprise Value | -1.49M | Income | -5.33M | Sales | 389.78K |
| Book/sh | 0.32 | Cash/sh | 0.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -0.01 | PEG | — |
| P/S | 0.26 | P/B | 0.07 | P/C | — |
| EV/EBITDA | 0.28 | EV/Sales | -3.82 | Quick Ratio | 2.89 |
| Current Ratio | 3.24 | Debt/Eq | 17.75 | LT Debt/Eq | — |
| EPS (ttm) | -2.26 | EPS next Y | -3.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-28 06:00 | ROA | -149.95% |
| ROE | -3.62% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -13.88% | Profit Margin | 0.00% | Shs Outstand | 4.62M |
| Shs Float | 4.33M | Short Float | 2.35% | Short Ratio | 3.32 |
| Short Interest | — | 52W High | 3.17 | 52W Low | 0.02 |
| Beta | 1.06 | Avg Volume | 10.57K | Volume | 10.19K |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.02 | Change | -61.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.02
Latest analyst target
3. DCF / Fair value
$-11.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.02
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-04-09 | init | Maxim Group | — → Buy | $2 |
- Risk On: Whats the beta of AlphaTime Acquisition Corp Equity Warrant stock - Portfolio Value Summary & Advanced Technical Signal Analysis - baoquankhu1.vn Mon, 06 Apr 2026 15
- Lipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring Process - TipRanks ue, 31 Mar 2026 14
- 11.1v 1300mAh 20C Stick LiPo Battery For Airsoft AEGs | 3-Pin Mini Tamiya Connector, Buffer Tube Fit - ruhrkanal.news Sun, 05 Apr 2026 12
- Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewswire Fri, 20 Jun 2025 07
- LIPO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sat, 14 Feb 2026 19
- Nasdaq to delist certain securities suspended from trading (NDAQ:NASDAQ) - Seeking Alpha Wed, 24 Sep 2025 07
- Lipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operations - The Business Journals hu, 26 Jun 2025 07
- LIPO SEC Filings - Lipella Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sun, 29 Jun 2025 06
- Lipella Pharmaceuticals(NASDAQ:LIPO) Faces Decline in Biotech Sector Nasdaq Composite - kalkinemedia.com Fri, 20 Jun 2025 07
- Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $LIPO - MarketBeat Wed, 21 Dec 2022 01
- Lipella Pharmaceuticals Inc. (LIPO) stock price, news, quote and history - sg.finance.yahoo.com Sat, 19 Aug 2023 16
- MUSC startup Lipo-Immuno Tech awarded two STTR grants to bring novel cancer therapies to patients - musc.edu ue, 04 Apr 2023 07
- Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire ue, 16 Dec 2025 08
- Xiaomi 17 Pro Max out of stock as fans swarm stores: Hi-tech, but cheaper, than iPhone 17 Pro Max? - Gulf News Mon, 29 Sep 2025 07
- Why Is vTv Therapeutics (VTVT) Stock Down 46% Today? - InvestorPlace Mon, 29 Jul 2024 07
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.54
+19.29%
|
0.45
+144.15%
|
0.18
-28.99%
|
0.26
|
| Operating Revenue |
|
0.54
+19.29%
|
0.45
|
0.00
|
0.00
|
| Cost Of Revenue |
|
3.61
+18.90%
|
3.04
+19.28%
|
2.55
+74.88%
|
1.46
|
| Reconciled Cost Of Revenue |
|
3.61
+18.90%
|
3.04
+19.28%
|
2.55
+74.88%
|
1.46
|
| Gross Profit |
|
-3.08
-18.83%
|
-2.59
-9.55%
|
-2.36
-97.38%
|
-1.20
|
| Operating Expense |
|
2.00
-7.10%
|
2.16
+853.50%
|
0.23
-68.51%
|
0.72
|
| Research And Development |
|
—
|
—
|
2.55
+74.88%
|
1.46
|
| Selling General And Administration |
|
2.00
-7.10%
|
2.16
+853.50%
|
0.23
-68.51%
|
0.72
|
| General And Administrative Expense |
|
2.00
-7.10%
|
2.16
+853.50%
|
0.23
-68.51%
|
0.72
|
| Other Gand A |
|
2.00
-7.10%
|
2.16
+853.50%
|
0.23
-68.51%
|
0.72
|
| Total Expenses |
|
5.62
+8.11%
|
5.20
+87.30%
|
2.77
+27.52%
|
2.18
|
| Operating Income |
|
-5.08
-7.05%
|
-4.75
-83.26%
|
-2.59
-35.17%
|
-1.92
|
| Total Operating Income As Reported |
|
-5.08
-7.05%
|
-4.75
-83.26%
|
-2.59
-35.17%
|
-1.92
|
| EBITDA |
|
-5.01
-8.83%
|
-4.61
-77.99%
|
-2.59
-39.25%
|
-1.86
|
| Normalized EBITDA |
|
-5.01
-8.83%
|
-4.61
-77.99%
|
-2.59
-39.25%
|
-1.86
|
| Reconciled Depreciation |
|
0.00
+71.28%
|
0.00
|
0.00
|
—
|
| EBIT |
|
-5.02
-8.86%
|
-4.61
-78.05%
|
-2.59
-39.25%
|
-1.86
|
| Net Income |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Pretax Income |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Net Non Operating Interest Income Expense |
|
0.06
-49.38%
|
0.13
+1700.55%
|
-0.01
-17.89%
|
-0.01
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.01
+12.86%
|
0.01
+40.65%
|
0.01
|
| Net Interest Income |
|
0.06
-49.38%
|
0.13
+1700.55%
|
-0.01
-17.89%
|
-0.01
|
| Interest Expense |
|
0.00
-100.00%
|
0.01
+12.86%
|
0.01
+40.65%
|
0.01
|
| Interest Income Non Operating |
|
0.06
-53.37%
|
0.14
+8114.30%
|
0.00
+1513.46%
|
0.00
|
| Interest Income |
|
0.06
-53.37%
|
0.14
+8114.30%
|
0.00
+1513.46%
|
0.00
|
| Other Income Expense |
|
—
|
—
|
-0.00
-100.08%
|
0.06
|
| Other Non Operating Income Expenses |
|
—
|
—
|
-0.00
-100.08%
|
0.06
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Net Income From Continuing Operation Net Minority Interest |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Net Income From Continuing And Discontinued Operation |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Net Income Continuous Operations |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Normalized Income |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Net Income Common Stockholders |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Diluted EPS |
|
-4.79
+22.24%
|
-6.16
-20.31%
|
-5.12
-97.06%
|
-2.60
|
| Basic EPS |
|
-4.79
+22.24%
|
-6.16
-20.31%
|
-5.12
-97.06%
|
-2.60
|
| Basic Average Shares |
|
1.05
+39.69%
|
0.75
+47.84%
|
0.51
-29.31%
|
0.72
|
| Diluted Average Shares |
|
1.05
+39.69%
|
0.75
+47.84%
|
0.51
-29.31%
|
0.72
|
| Diluted NI Availto Com Stockholders |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
2.67
-25.25%
|
3.58
-39.88%
|
5.95
+195.60%
|
2.01
|
| Current Assets |
|
2.62
-23.68%
|
3.43
-40.87%
|
5.80
+220.74%
|
1.81
|
| Cash Cash Equivalents And Short Term Investments |
|
2.18
-33.67%
|
3.29
-35.69%
|
5.12
+198.75%
|
1.71
|
| Cash And Cash Equivalents |
|
2.18
-33.67%
|
3.29
-35.69%
|
5.12
+262.26%
|
1.41
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
0.30
|
| Receivables |
|
0.08
+162.38%
|
0.03
-71.59%
|
0.11
|
0.00
|
| Other Receivables |
|
0.08
+162.38%
|
0.03
-71.59%
|
0.11
|
—
|
| Prepaid Assets |
|
0.35
+236.71%
|
0.10
-81.69%
|
0.56
+501.71%
|
0.09
|
| Total Non Current Assets |
|
0.06
-61.72%
|
0.15
-1.94%
|
0.15
-26.36%
|
0.20
|
| Net PPE |
|
0.06
-61.72%
|
0.15
-1.94%
|
0.15
-26.36%
|
0.20
|
| Gross PPE |
|
0.19
-32.09%
|
0.28
-0.45%
|
0.28
+35.10%
|
0.20
|
| Accumulated Depreciation |
|
-0.13
-2.26%
|
-0.13
-1.34%
|
-0.13
|
—
|
| Machinery Furniture Equipment |
|
0.14
+0.00%
|
0.14
+11.47%
|
0.13
|
—
|
| Other Properties |
|
0.05
-65.40%
|
0.14
-10.39%
|
0.15
-26.36%
|
0.20
|
| Total Liabilities Net Minority Interest |
|
0.75
+74.34%
|
0.43
-66.05%
|
1.27
+116.26%
|
0.59
|
| Current Liabilities |
|
0.75
+95.77%
|
0.39
-67.29%
|
1.18
+245.91%
|
0.34
|
| Payables And Accrued Expenses |
|
0.71
+138.68%
|
0.30
-64.95%
|
0.84
+206.13%
|
0.28
|
| Payables |
|
0.39
+104.24%
|
0.19
-50.55%
|
0.38
+719.52%
|
0.05
|
| Accounts Payable |
|
0.39
+181.27%
|
0.14
-64.09%
|
0.38
+719.52%
|
0.05
|
| Current Accrued Expenses |
|
0.32
+200.40%
|
0.11
-76.97%
|
0.46
+101.04%
|
0.23
|
| Total Tax Payable |
|
—
|
0.05
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.05
-46.64%
|
0.09
-73.23%
|
0.33
+415.90%
|
0.06
|
| Current Debt |
|
—
|
—
|
0.28
+1000.00%
|
0.03
|
| Other Current Borrowings |
|
—
|
—
|
0.28
+1000.00%
|
0.03
|
| Current Capital Lease Obligation |
|
0.05
-46.64%
|
0.09
+53.14%
|
0.06
+47.13%
|
0.04
|
| Other Current Liabilities |
|
—
|
—
|
0.07
+35.23%
|
0.05
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.05
-50.79%
|
0.10
-61.30%
|
0.25
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.05
-50.79%
|
0.10
-55.92%
|
0.22
|
| Long Term Debt |
|
—
|
—
|
—
|
0.05
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.05
-50.79%
|
0.10
-42.83%
|
0.17
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Stockholders Equity |
|
1.92
-38.96%
|
3.14
-32.75%
|
4.68
+228.45%
|
1.42
|
| Common Stock Equity |
|
1.92
-38.96%
|
3.14
-32.75%
|
4.68
+228.48%
|
1.42
|
| Capital Stock |
|
0.00
+105.33%
|
0.00
-86.93%
|
0.00
+5.13%
|
0.00
|
| Common Stock |
|
0.00
+61.33%
|
0.00
-86.93%
|
0.00
+48.32%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Share Issued |
|
1.21
+59.75%
|
0.76
+5.40%
|
0.72
+0.00%
|
0.72
|
| Ordinary Shares Number |
|
1.21
+59.75%
|
0.76
+5.40%
|
0.72
+0.00%
|
0.72
|
| Additional Paid In Capital |
|
17.26
+28.15%
|
13.47
+29.75%
|
10.38
+129.13%
|
4.53
|
| Retained Earnings |
|
-15.34
-48.59%
|
-10.32
-80.97%
|
-5.70
-83.60%
|
-3.11
|
| Total Equity Gross Minority Interest |
|
1.92
-38.96%
|
3.14
-32.75%
|
4.68
+228.45%
|
1.42
|
| Total Capitalization |
|
1.92
-38.96%
|
3.14
-32.75%
|
4.68
+217.30%
|
1.47
|
| Working Capital |
|
1.86
-38.80%
|
3.04
-34.13%
|
4.62
+214.90%
|
1.47
|
| Invested Capital |
|
1.92
-38.96%
|
3.14
-36.48%
|
4.95
+230.39%
|
1.50
|
| Total Debt |
|
0.05
-65.15%
|
0.14
-68.20%
|
0.43
+51.79%
|
0.28
|
| Capital Lease Obligations |
|
0.05
-65.15%
|
0.14
-11.60%
|
0.15
-25.70%
|
0.21
|
| Net Tangible Assets |
|
1.92
-38.96%
|
3.14
-32.75%
|
4.68
+228.45%
|
1.42
|
| Tangible Book Value |
|
1.92
-38.96%
|
3.14
-32.75%
|
4.68
+228.48%
|
1.42
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
0.00
-86.90%
|
0.03
|
| Line Of Credit |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Equity |
|
0.00
|
—
|
—
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.95
-25.41%
|
-3.15
-72.03%
|
-1.83
-85.10%
|
-0.99
|
| Cash Flow From Continuing Operating Activities |
|
-3.95
-25.41%
|
-3.15
-72.03%
|
-1.83
-85.10%
|
-0.99
|
| Net Income From Continuing Operations |
|
-5.02
-8.60%
|
-4.62
-77.81%
|
-2.60
-39.25%
|
-1.87
|
| Depreciation Amortization Depletion |
|
0.00
+71.28%
|
0.00
|
0.00
|
—
|
| Depreciation |
|
0.00
+71.28%
|
0.00
|
—
|
—
|
| Depreciation And Amortization |
|
0.00
+71.28%
|
0.00
|
0.00
|
—
|
| Other Non Cash Items |
|
0.20
+65.02%
|
0.12
+1160.92%
|
0.01
+40.65%
|
0.01
|
| Stock Based Compensation |
|
0.75
-44.69%
|
1.36
+81.30%
|
0.75
+2.55%
|
0.73
|
| Operating Gains Losses |
|
—
|
—
|
0.75
+1410.30%
|
-0.06
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.75
+2.55%
|
0.73
|
| Change In Working Capital |
|
0.11
+1343.25%
|
-0.01
-195.64%
|
0.01
-95.18%
|
0.20
|
| Change In Receivables |
|
—
|
—
|
-0.11
-264.63%
|
0.07
|
| Change In Prepaid Assets |
|
-0.24
-153.06%
|
0.46
+197.97%
|
-0.47
-571.10%
|
-0.07
|
| Change In Payables And Accrued Expense |
|
0.41
+174.82%
|
-0.55
-192.59%
|
0.59
+201.30%
|
0.20
|
| Change In Accrued Expense |
|
0.16
+153.06%
|
-0.30
-218.47%
|
0.26
+46.43%
|
0.17
|
| Change In Payable |
|
0.25
+201.56%
|
-0.25
-173.00%
|
0.34
+1409.19%
|
0.02
|
| Change In Account Payable |
|
0.25
+201.56%
|
-0.25
-173.00%
|
0.34
+1409.19%
|
0.02
|
| Change In Other Working Capital |
|
-0.05
-164.43%
|
0.08
+171.59%
|
-0.11
-264.63%
|
0.07
|
| Change In Other Current Assets |
|
-0.00
+73.37%
|
-0.00
-518.03%
|
0.00
-71.43%
|
0.00
|
| Change In Other Current Liabilities |
|
—
|
—
|
0.02
-22.73%
|
0.02
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.01
-104.80%
|
0.30
+200.00%
|
-0.30
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.01
-104.80%
|
0.30
+200.00%
|
-0.30
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Capital Expenditure |
|
—
|
-0.01
|
—
|
—
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
0.30
+200.00%
|
-0.30
|
| Purchase Of Investment |
|
—
|
—
|
—
|
-0.30
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
0.30
|
—
|
| Financing Cash Flow |
|
2.84
+112.62%
|
1.34
-74.49%
|
5.24
+149.82%
|
2.10
|
| Cash Flow From Continuing Financing Activities |
|
2.84
+112.62%
|
1.34
-74.49%
|
5.24
+149.82%
|
2.10
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.28
-200.00%
|
0.28
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
0.28
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.28
|
0.00
|
—
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
0.28
|
0.00
|
| Long Term Debt Payments |
|
—
|
-0.25
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
—
|
-0.25
-190.91%
|
0.28
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.28
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.00
+100.00%
|
-0.28
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
—
|
0.00
-100.00%
|
4.96
+136.71%
|
2.10
|
| Proceeds From Stock Option Exercised |
|
—
|
1.61
|
0.00
|
—
|
| Changes In Cash |
|
-1.11
+39.34%
|
-1.83
-149.30%
|
3.71
+359.42%
|
0.81
|
| Beginning Cash Position |
|
3.29
-35.69%
|
5.12
+262.26%
|
1.41
+133.02%
|
0.61
|
| End Cash Position |
|
2.18
-33.67%
|
3.29
-35.69%
|
5.12
+262.26%
|
1.41
|
| Free Cash Flow |
|
-3.95
-24.84%
|
-3.16
-72.82%
|
-1.83
-85.10%
|
-0.99
|
| Interest Paid Supplemental Data |
|
0.01
+4.84%
|
0.01
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
—
|
0.00
-100.00%
|
4.96
+136.71%
|
2.10
|
| Issuance Of Capital Stock |
|
2.84
+76.34%
|
1.61
-67.53%
|
4.96
+136.71%
|
2.10
|
| Net Preferred Stock Issuance |
|
2.84
+76.34%
|
1.61
|
—
|
—
|
| Preferred Stock Issuance |
|
2.84
+76.34%
|
1.61
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-31 View
- 8-K2026-02-04 View
- 10-Q2025-11-14 View
- 8-K2025-10-21 View
- 8-K2025-10-09 View
- 8-K2025-09-18 View
- 10-Q2025-08-14 View
- 8-K2025-06-25 View
- 8-K2025-06-20 View
- 8-K2025-06-16 View
- 8-K2025-05-16 View
- 8-K2025-05-15 View
- 10-Q2025-05-14 View
- 8-K2025-04-14 View
- 8-K2025-04-09 View
- 42025-04-07 View
- 8-K2025-04-07 View
- 10-K2025-03-28 View
- 8-K2025-03-18 View
- 42025-03-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|